as prenatal genetic diagnosis for numeric chromosomal abnormalities (trisomy 21) at last reached its desired goal of becoming a definitive test (not a screen)? Can we relegate our invasive diagnostic procedures-chorionic villus sampling (CVS) and amniocentesis-to the museum? The contributions of Bianchi et al 1 (see p. 890) and others earlier this year 2,3 take us a considerable distance. Of course, a few steps remain before declaring victory.
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Definitive noninvasive fetal diagnosis long has been considered tantalizingly close, first through analysis of intact fetal cells in maternal blood and, more recently, through cell-free fetal DNA. The first detection of fetal trisomy (trisomy 18) from maternal blood was made in 1991, based on recovery of nucleated fetal red blood cells and analysis by fluorescence in situ hybridization. 4 Subsequent confirmation was made by several other groups, and successful cases accrued. 5, 6 A multicenter National Institute of Child Health and Human Development collaborative study was begun, with its 2002 report showing 74% detection of trisomy 21 cases with no false positives. 7 Recovery of intact fetal cells at that time was considered proven; however, the method was laborious and it was hindered by inconsistent recovery.
It had been known previously that cell-free DNA was present in the plasma of adults with cancer, but, in 1997, Lo's discovery of cell-free fetal DNA in maternal blood opened the door for its application to noninvasive prenatal genetic diagnosis. 8 In fact, earlier reports of the presence of paternal ␤-thalassemia mutations in maternal blood 9 (and, hence, obligatorily of fetal origin) may have been the result of cell-free fetal DNA in maternal plasma rather than intact fetal cells, as was generally assumed at the time.
Approximately 5% of cell-free DNA in maternal plasma is believed to be fetal in origin. Distinguishing trisomic from nontrisomic pregnancies can be based on quantifying the total number of chromosome 21 transcripts in maternal blood using a technique called massive parallel genomic sequencing. A pregnancy with a fetus with trisomy 21 will have more chromosome 21 transcripts than one carrying a fetus without trisomy 21 because the trisomic fetus has three 21 chromosomes rather than the usual two. If 5% of cell-free DNA in maternal blood were of fetal origin, a mother carrying a fetus with trisomy 21 should have 2.5% more chromosome 21 transcripts than if her fetus were not trisomic.
The study of Bianchi and colleagues collected samples prospectively. Joe Leigh Simpson, MD recruitment criteria," 5.6% "did not pass the specimen quality requirements," and 1.4% did not meet "quality control requirements." Still, all 86 trisomy 21 cases were detected using a protocol in which two cases were sequenced and analyzed concurrently (2-plex What are the next steps? One obligatory task is to accrue prospective data in which results are acted on clinically. Although reports have shown high sensitivity and specificity, studies have used archived or accumulated samples. This approach is efficient and entirely appropriate at the initial stage, but it does not reflect the "real life" situation faced by an active clinical laboratory processing many samples under pressure to produce a rapid and nearly error-free turnaround. Current vendors also envision shipping samples nationwide to their single Clinical Laboratory Improvement Act laboratory; therefore, it is necessary to confirm that transport does not lead to a deterioration of the sample and thus affect performance. Studies also need to be performed on the general pregnant population, not just on those women who are high-risk. Finally, will costs be competitive with those of extant tests?
Suppose, however, that detection rates with cellfree fetal DNA truly are 98% or higher and competitive in cost. This detection rate would be higher than the 85-95% detection rate expected by modeling on the basis of maternal serum analyte and nuchal translucency values. That is, cell-free fetal DNA for aneuploidy screening already may be superior to the existing method. An approach based simply on number of 21 transcripts also would be easier to explain in counseling. Results probably would be available earlier in pregnancy, and onsite ultrasound expertise would not be obligatory.
The holy grail is not yet another aneuploidy screening tool, but a test that provides definitive diagnosis and does not require a second step (ie, a test such as CVS or amniocentesis) before communicating a near-definitive answer. Of course, it would be prudent initially to perform confirmatory CVS or amniocentesis to verify a cell-free fetal DNA diagnosis. The occasional false-positive result will occur, perhaps because of a twin that has vanished (because it was aneuploid and, hence, not viable). However, one would expect cell-free fetal DNA trisomy to be confirmed in almost all cases based on the studies published to date. I am confident that analysis of maternal blood for fetal aneuploidy could, and probably should, replace maternal serum analytes as the preferred test for aneuploidy. Of course, this will follow the seemingly obligatory period of contemplation and guideline generation, but, one hopes, not a randomized clinical trial ineluctably delaying translation of a new and exciting technology! Once cell-free fetal DNA analysis is vetted for routine use, we will face another conundrum, because it currently seems designed to detect only select aneuploidies. Moreover, trisomy 13 and trisomy 18 have not been detected as reliably as has trisomy 21. In fact, another diagnostic advance is array comparative genome hybridization, which identifies not only aneuploidies but also copy number variants (microdeletions and microduplications) too small to be evident by traditional karyotype (Wapner R. A multicenter, prospective, masked comparison of chromosomal microarray with standard karyotyping for routine and high risk prenatal diagnosis [abstract] . Am J Obstet Gynecol 2012;206:S2). Now performed on chorionic villi or amniotic fluid cells, array comparative genome hybridization is less suitable for an admixed DNA sample (ie, cell-free fetal DNA admixed with maternal cell-free DNA) than a "pure" DNA sample (ie, cellfree fetal DNA only). Further, array comparative genome hybridization and new-generation sequencing will allow us to detect not only copy number variants but many single gene perturbations, not only those causing Mendelian disorders but those we will surely discover as indicative of fetal growth restriction, placental abnormalities, and preterm birth. We then could envision genuine therapeutic intervention rather than merely increasing obstetric surveillance. If we wish to incorporate array comparative genome hybridization or fetal genome sequencing, would it not be more efficient to have intact fetal cells? Although fetal cell recovery is in a relative diastole, this approach continues to be pursued actively by several groups who have isolated and analyzed fetal trophoblasts in maternal blood successfully. 10 In conclusion, studies show that analysis of cellfree fetal DNA is now valid for detecting trisomy 21. Yet, the rationale for studying intact fetal cells (nuclei) could change the game again. In 2012, however, we await prospective "real time" data that should demonstrate whether our health care system has indeed successfully translated this long-sought goal.
